Rita Garcia‐Martinez, Alex Rovira, Juli Alonso, Carlos Jacas, Macarena Simón‐Talero, Laia Chavarria, Víctor Vargas, Juan Córdoba – 11 October 2010 – Hepatic encephalopathy (HE) is a common complication of cirrhosis that is associated with brain atrophy and may participate in impaired cognitive function after liver transplantation. This study analyzes the relationship of HE with cognitive function and brain volume after transplantation.

Albert Parés, Llorenç Caballería – 11 October 2010

Ido Laish, Marius Braun, Eytan Mor, Jaqueline Sulkes, Yael Harif, Ziv Ben Ari – 11 October 2010 – Features of metabolic syndrome are not uncommon in patients after liver transplantation. To examine the prevalence and risk factors of posttransplantation metabolic syndrome (PTMS), the files of 252 transplant recipients (mean age, 54.5 ± 2.8 years, 57.9% male) were reviewed for pretransplant and posttransplant clinical and laboratory parameters (mean follow‐up, 6.2 ± 4.4 years).

Rehana Begum, Denise Harnois, Raj Satyanarayana, Murli Krishna, Kevin C. Halling, George P. Kim, Justin H. Nguyen, Andrew P. Keaveny – 11 October 2010 – Although tumor transmission through liver transplantation (LT) is a rare occurrence, the consequences can be devastating, even when a very aggressive management approach is adopted. We report the case of a donor‐derived small cell neuroendocrine tumor (NET) in a patient who underwent LT for cholangiocarcinoma. Despite locoregional therapy, chemotherapy and ultimately retransplantation, the patient died from metastases.

James E. Nelson, Laura Wilson, Elizabeth M. Brunt, Matthew M. Yeh, David E. Kleiner, Aynur Unalp‐Arida, Kris V. Kowdley – 11 October 2010 – Previous studies examining the relationship between hepatic iron deposition and histological severity in nonalcoholic fatty liver disease (NAFLD) have been inconclusive. The goal of this study was to examine the relationship between hepatic iron deposition and liver histology in 849 patients enrolled in the Nonalcoholic Steatohepatitis Clinical Research Network.

Joost P.H. Drenth, Melissa Chrispijn, David M. Nagorney, Patrick S. Kamath, Vicente E. Torres – 11 October 2010

Gianni Testino, Paolo Borro – 11 October 2010

Marrero Jorge A., El‐ Serag Hashem B. – 11 October 2010

Albillos Agustín, Zamora Javier – 11 October 2010

Caroline Hora, Pamela Romanque, Jean‐François F. Dufour – 11 October 2010 – Hepatocellular carcinoma (HCC) is a common cause of cancer‐related death. Sorafenib prolongs survival of patients with advanced disease and is approved for the systemic treatment of unresectable HCC. It possesses antiangiogenic and antiproliferative properties by way of inhibition of the receptor tyrosine kinases vascular endothelial growth factor receptor 2 (VEGFR‐2) and platelet‐derived growth factor receptor‐beta 1/2 (PDGFR‐β) and the kinase RAF.